Axa
SYRE icon

Axa’s Spyre Therapeutics SYRE Stock Holding History

Axa’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,797
Closed -$2.11M – 1237
2021
Q4 		$2.11M Buy
17,797
+210
+1% +$33.1K 0.01% 834
2021
Q3 		$3.5M Buy
17,587
+613
+4% +$107K 0.01% 763
2021
Q2 		$2.95M Buy
16,974
+17
+0.1% +$3.09K 0.01% 809
2021
Q1 		$3.36M Buy
16,957
+397
+2% +$76.2K 0.01% 768
2020
Q4 		$3.26M Buy
16,560
+4,355
+36% +$903K 0.01% 779
2020
Q3 		$2.16M Buy
+12,205
New +$2.26M 0.01% 799

Other funds holding SYRE

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Axa's SYRE Position: Q1 2022 in Review

Axa sold out of Spyre Therapeutics (SYRE) in Q1 2022, closing a stake of 17,797 shares — an estimated $2.11M sold.

Axa first reported a position in SYRE in Q3 2020 and held it in 6 quarters. The position peaked at $3.5M in Q3 2021. 83 funds tracked by Wall St. Rank hold SYRE as of Q1 2022.

  • Axa reported no remaining Spyre Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Axa sold 17,797 Spyre Therapeutics shares in Q1 2022, an estimated $2.11M.
  • Axa first reported a position in Spyre Therapeutics in Q3 2020 and held it in 6 quarters.
  • Axa's Spyre Therapeutics position peaked at $3.5M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2022.

Based on Axa's 13F filing for Q1 2022, filed 13 May 2022.